Skip to main content
BIOVENTIX PLC logo

BIOVENTIX PLC — Investor Relations & Filings

Ticker · BVXP ISIN · GB00B4QVDF07 LEI · 213800225MHX7LZQY108 IL Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2019-11-20 Regulatory Filings
Country GB United Kingdom
Listing IL BVXP

About BIOVENTIX PLC

https://www.bioventix.com/

Bioventix PLC is a biotechnology company that specializes in the development, creation, and commercial supply of high-affinity sheep monoclonal antibodies (SMAs). These antibodies are utilized by global diagnostic companies as critical components in clinical diagnostic platforms, particularly for blood testing immunoassays. The company's portfolio supports a variety of applications, including diagnostics for cardiovascular conditions (troponin), oncology, and neurodegenerative diseases such as Alzheimer's. In addition to its core antibody products, Bioventix also provides ELISA kits for monitoring exposure to industrial pollutants and offers contract services for the development of new SMAs for healthcare organizations.

Recent filings

Filing Released Lang Actions
Full accounts made up to 2019-06-30
Regulatory Filings
2019-11-20 English
Bioventix Plc - Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document explicitly details a transaction involving the sale of shares by a Director/PDMR (Person Discharging Managerial Responsibilities), specifically the Non-Executive Chairman, Ian Nicholson. It includes specific details like the number of shares sold, the sale price, and the resulting holding. This content directly matches the definition of a Director's Dealing report, which corresponds to the filing code DIRS.
2019-10-28 English
Bioventix Plc - Results for the year ended 30 June 2019
Audit Report / Information Classification · 98% confidence The document explicitly states it announces the "audited results for the year ended 30 June 2019" for Bioventix plc. It contains detailed financial highlights (Revenue, Profit before tax, Cash), a review of the financial results for the year, dividend announcements, and forward-looking statements regarding research and development. This structure is characteristic of a comprehensive annual financial report, which aligns with the definition of an Annual Report (10-K), although the document itself is likely the press release or preliminary filing accompanying the full statutory filing. Given the depth of financial detail and the explicit mention of 'audited results' for the full fiscal year, it is classified as the Annual Report (10-K) or the primary document summarizing it. Since the document is quite long (46k characters) and contains the core financial narrative, it is not a simple RPA or ER. FY 2019
2019-10-21 English
Bioventix Plc - Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured fields detailing an 'acquisition or disposal of voting rights' by 'CANACCORD GENUITY GROUP INC' concerning shares in 'BIOVENTIX PLC'. This form (TR-1) is the standard notification required under the EU Transparency Directive (implemented in the UK via DTR5) when an investor's holding crosses a major threshold (e.g., 5%, 10%, etc.). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant share ownership levels crossing thresholds.
2019-10-15 English
Bioventix Plc - Notice of Results
Report Publication Announcement Classification · 99% confidence The document is titled "Bioventix Plc - Notice of Results" and explicitly states two key pieces of information: 1) The date the preliminary results for the year ended 30 June 2019 will be released (October 21, 2019), and 2) The date and location of the Annual General Meeting (AGM) on December 12. Since the document is short (2214 chars) and serves primarily to announce the timing of future reports (preliminary results) and the AGM details, it fits the definition of a Report Publication Announcement (RPA) or potentially an AGM-R if the AGM details were the primary focus. However, because it announces *when* the results will be released, it strongly aligns with RPA, which covers announcements regarding the timing/publication of reports. It is not the full results (ER/IR/10-K) nor is it the AGM presentation itself (AGM-R). Given the dual announcement nature, RPA is the most appropriate fit for announcing the publication schedule of other documents.
2019-09-11 English
Bioventix Plc - Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured fields typical of regulatory disclosures regarding changes in share ownership thresholds. Specifically, it details the 'NOTIFICATION OF MAJOR HOLDINGS' for Bioventix plc, referencing the date the threshold was crossed (27/08/19) and the resulting percentage of voting rights. This type of filing, which reports changes in significant shareholdings, corresponds directly to the definition of Major Shareholding Notification (MRQ).
2019-08-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.